Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.57 -2.5%	$19.74	$13.40 ▼ $25.23	$3.70B	0.64	1.96 million shs	1.63 million shs
AMRN Amarin	$16.22 +3.2%	$11.93	$7.08 ▼ $18.00	$325.31M	0.71	81,484 shs	170,121 shs
MDCO Medicines	$84.90	$84.90	$17.81 ▼ $84.98	$6.77B	1.1	9.55 million shs	N/A
RDY Dr. Reddy's Laboratories	$15.03 -0.3%	$14.63	$12.26 ▼ $16.89	$12.58B	0.33	1.52 million shs	1.45 million shs
RETA Reata Pharmaceuticals	$172.36	$171.30	$21.83 ▼ $172.46	$6.58B	1.42	1.09 million shs	N/A

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-2.60%	+2.41%	+33.17%	+36.12%
AMRN Amarin	0.00%	+25.28%	+35.43%	+75.30%	+14.17%
MDCO Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
RDY Dr. Reddy's Laboratories	0.00%	-1.06%	+2.39%	+14.23%	-1.16%
RETA Reata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.5974 of 5 stars	4.4	3.0	0.0	0.0	2.6	4.2	2.5
AMRN Amarin	0.7325 of 5 stars	0.5	5.0	0.0	0.0	3.2	0.0	0.6
MDCO Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	2.7901 of 5 stars	2.5	4.0	1.7	0.0	2.1	0.0	1.9
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	29.23% Upside
AMRN Amarin	1.00	Sell	$12.00	-26.02% Downside
MDCO Medicines	0.00	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	12.77% Upside
RETA Reata Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MDCO, AMRN, RETA, ACAD, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/25/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$7.00 ➝ $12.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
6/5/2025	RDY Dr. Reddy's Laboratories	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	RDY Dr. Reddy's Laboratories	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$14.44 ➝ $16.90

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.77	$0.69 per share	31.38	$4.40 per share	4.90
AMRN Amarin	$228.61M	1.47	N/A	N/A	$23.62 per share	0.69
MDCO Medicines	$6.14M	1,102.36	N/A	N/A	($0.30) per share	-283.00
RDY Dr. Reddy's Laboratories	$3.81B	3.29	$1.03 per share	14.59	$4.73 per share	3.18
RETA Reata Pharmaceuticals	$23.48M	280.05	N/A	N/A	($1.79) per share	-96.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	15.74	28.38	4.77	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
AMRN Amarin	-$82.18M	-$3.64	N/A	N/A	N/A	-41.07%	-17.21%	-12.16%	7/30/2025 (Estimated)
MDCO Medicines	-$123.16M	-$2.91	N/A	N/A	N/A	N/A	N/A	-25.70%	N/A
RDY Dr. Reddy's Laboratories	$663M	$0.66	22.77	18.33	5.32	17.38%	17.98%	12.24%	7/25/2025 (Estimated)
RETA Reata Pharmaceuticals	-$311.90M	N/A	0.00	N/A	N/A	N/A	-922.50%	-73.39%	N/A

Latest MDCO, AMRN, RETA, ACAD, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/25/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.19	N/A	N/A	N/A	$88.27 billion	N/A
5/9/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	$0.22	+$0.02	$0.22	$83.70 billion	$996.17 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	AMRN Amarin	-$0.06	-$0.04	+$0.02	-$0.04	$50.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
MDCO Medicines	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.08	0.53%	N/A	12.12%	N/A
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
AMRN Amarin	N/A	3.53	2.55
MDCO Medicines	21.45	0.77	0.77
RDY Dr. Reddy's Laboratories	0.02	1.92	1.37
RETA Reata Pharmaceuticals	0.84	3.21	3.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AMRN Amarin	22.25%
MDCO Medicines	N/A
RDY Dr. Reddy's Laboratories	3.85%
RETA Reata Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
AMRN Amarin	1.96%
MDCO Medicines	8.41%
RDY Dr. Reddy's Laboratories	2.00%
RETA Reata Pharmaceuticals	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	120.00 million	Optionable
AMRN Amarin	360	20.71 million	20.30 million	Optionable
MDCO Medicines	62	79.72 million	N/A	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.89 million	818.19 million	Optionable
RETA Reata Pharmaceuticals	321	38.15 million	27.93 million	Optionable

MDCO, AMRN, RETA, ACAD, and RDY Headlines

Recent News About These Companies

Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects

February 12, 2025 | fiercebiotech.comF

Arbe Robotics (NASDAQ:ARBE) Stock Quotes, Forecast and News Summary

November 1, 2024 | benzinga.com

What to Know: How Israel Could Retaliate Against Iran

October 27, 2024 | nytimes.com

Reta Hendrickson

September 11, 2024 | newsandsentinel.comN

Reata rockets on data for Nrf2 drug reacquired from AbbVie

August 8, 2024 | pharmaphorum.comP

Lazard hires veteran healthcare dealmaker Colocci as vice chairman

May 9, 2024 | investing.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 18, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 16, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 11, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 9, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 4, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 2, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 28, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 26, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 21, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 19, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 14, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 12, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 7, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 5, 2024 | accesswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Growth Stocks Too Small for Institutions to Buy
By Gabriel Osorio-Mazilli | June 19, 2025
View 3 Growth Stocks Too Small for Institutions to Buy
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Dollar Tree Stock Hits a Pivotal Point, Can It Continue?
By Gabriel Osorio-Mazilli | June 27, 2025
View Dollar Tree Stock Hits a Pivotal Point, Can It Continue?
Why Dollar General May Be Retail’s Most Undervalued Rebound
By Jeffrey Neal Johnson | June 2, 2025
View Why Dollar General May Be Retail’s Most Undervalued Rebound

MDCO, AMRN, RETA, ACAD, and RDY Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.57 -0.55 (-2.49%)

As of 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Amarin NASDAQ:AMRN

$16.22 +0.51 (+3.25%)

As of 04:00 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Medicines NASDAQ:MDCO

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Dr. Reddy's Laboratories NYSE:RDY

$15.03 -0.04 (-0.27%)

As of 03:58 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time